[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Eikon Therapeutics Inc (EIKN)

Eikon Therapeutics Inc (EIKN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 679,771
  • Shares Outstanding, K 54,165
  • Annual Sales, $ 0 K
  • Annual Income, $ -324,250 K
  • EBIT $ -362 M
  • EBITDA $ -338 M
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.32

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $-1.74
  • Number of Estimates 4
  • High Estimate $-1.70
  • Low Estimate $-1.79
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.17%

Price Performance

See More
Period Period Low Period High Performance
1-Month
8.90 +41.01%
on 07/27/26
14.51 -13.50%
on 08/19/26
+3.65 (+41.01%)
since 07/24/26
3-Month
8.01 +56.68%
on 06/11/26
14.51 -13.50%
on 08/19/26
+1.64 (+15.03%)
since 05/22/26

Most Recent Stories

More News
Eikon Therapeutics to Participate in Investor Conferences in September 2026

MILLBRAE, Calif., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines...

EIKN : 12.55 (+12.46%)
Eikon Therapeutics to Participate in KOL Event on Therapeutic Use of PARP Inhibitors in Oncology Hosted by Cantor Fitzgerald

MILLBRAE, Calif., Aug. 18, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines...

EIKN : 12.55 (+12.46%)
Eikon Therapeutics Reports Second Quarter 2026 Financial Results and Provides Clinical Updates

Eikon announced seven abstracts accepted for presentation at the European Society for Medical Oncology (ESMO) Congress 2026 highlighting progress across Eikon’s oncology portfolio, including clinical...

EIKN : 12.55 (+12.46%)
Eikon Therapeutics Announces Dose Selection for TeLuRide-006, an Ongoing Adaptive Phase 2/3 Trial of EIK1001 in Advanced Melanoma

Selected 0.60 mg/m 2 as the single dose for the TeLuRide-006 study going forward for patients randomized to EIK1001 treatment, in accord with a recommendation of the independent Data Monitoring Committee...

EIKN : 12.55 (+12.46%)
Eikon Therapeutics Announces Dose Selection for TeLuRide-006, an Ongoing Adaptive Phase 2/3 Trial of EIK1001 in Advanced Melanoma

Selected 0.60 mg/m2 as the single dose for the TeLuRide-006 study going forward for patients randomized to EIK1001 treatment, in accord with a...

EIKN : 12.55 (+12.46%)
Eikon Therapeutics Appoints Johnny Bennett, Ph.D. to its Scientific Advisory Board

MILLBRAE, Calif., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines...

EIKN : 12.55 (+12.46%)
Eikon Therapeutics Announces First Patient Dosed in TeLuRide-008, a Registrational Phase 2/3 Trial of EIK1001 in Non-Small Cell Lung Cancer

MILLBRAE, Calif., July 27, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (Eikon), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address...

EIKN : 12.55 (+12.46%)
Eikon Therapeutics Announces Seven Abstracts Accepted for Presentation at the 2026 European Society of Medical Oncology (ESMO) Congress

Presentations to cover updates across Eikon’s clinical pipeline including:  Updated data from TeLuRide-005, an ongoing Phase 2 trial of EIK1001, a TLR7/8 dual agonist, plus pembrolizumab and...

EIKN : 12.55 (+12.46%)
Eikon Therapeutics to Join the Russell 3000® Index

MILLBRAE, Calif., June 25, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines...

EIKN : 12.55 (+12.46%)
Eikon Therapeutics Announces the Appointment of Ma. Fatima D. Francisco to its Board of Directors

MILLBRAE, Calif., June 08, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines...

EIKN : 12.55 (+12.46%)

Business Summary

Eikon Therapeutics Inc. is a late-stage clinical biopharmaceutical company. It involved in developing medicines to address serious unmet medical needs. Eikon Therapeutics Inc. is based in MILLBRAE, Calif.

See More

Key Turning Points

3rd Resistance Point 14.75
2nd Resistance Point 13.78
1st Resistance Point 13.17
Last Price 12.55
1st Support Level 11.59
2nd Support Level 10.62
3rd Support Level 10.01

See More

52-Week High 17.40
Fibonacci 61.8% 13.77
Fibonacci 50% 12.65
Last Price 12.55
Fibonacci 38.2% 11.53
52-Week Low 7.90

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.